Global Cluster Headache Drug Market Overview:
Cluster headache, also known as Horton's syndrome, is characterised by a series of brief but intense headaches on one side of the head that occur every day for weeks or months. Cluster headaches arise when a person has a series of attacks that range from weeks to months and are followed by long periods of relief. Cluster headaches develop at the same time every year due to their cyclical nature.
- Increasing prevalence of cluster headaches and migraine
- Increased television viewing and computer usage
- Growing geriatric population
- Lack of awareness amongst people and healthcare providers about cluster headaches
- Unfavorable health care policies
- Application of latest technologies in the health care industry
- Growth potential in developing countries
- Increasing measure by government to lessen healthcare expenditure
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Pfizer Inc (United States), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), TrioxBio Inc (Israel), Aurobindo Pharma (India), Endo Pharmaceuticals Inc (Ireland) and Chengdu Tiantaishan pharmaceutical Co.,Ltd (China). Additionally, following companies can also be profiled that are part of our coverage like WOCKHARDT (India) and Shanghai Soho Yiming Pharmaceutical Co., Ltd (China). Analyst at AMA Research see United States Players to retain maximum share of Global Cluster Headache Drug market by 2026. Considering Market by Drug, the sub-segment i.e. Fast-Acting Drugs will boost the Cluster Headache Drug market. Considering Market by Mechanism of Action, the sub-segment i.e. Corticosteroids will boost the Cluster Headache Drug market. Considering Market by Treatment, the sub-segment i.e. Medication will boost the Cluster Headache Drug market. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Cluster Headache Drug market. Considering Market by Diagnosis, the sub-segment i.e. Neurological Examination will boost the Cluster Headache Drug market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Cluster Headache Drug market.
Latest Market Insights:
In April 2017, electroCore, Inc received the US FDA approval for gammaCore device, a non-invasive vagus nerve stimulator aimed to treat pain associated with episodic cluster headache in adult patients. Gammacore the first and only FDA-approved device for the prevention of cluster headache. It is a safe and effective treatment when compared to other treatments
In June 2019, Eli Lilly and Company received the US FDA approval for Emgality (Galcanezumab). This drug became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks. It belongs to a new class of drugs called CGRP inhibitors that are used to prevent migraines or reduce their frequency
What Can be Explored with the Cluster Headache Drug Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Cluster Headache Drug Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Cluster Headache Drug
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cluster Headache Drug market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cluster Headache Drug market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Cluster Headaches Drug, Government Regulatory and Research Organizations and End-Use Industries.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Frequently Asked Questions (FAQ):1. What is the growth rate predicted for the Global Cluster Headache Drug Market?
The Cluster Headache Drug market is expected to see a CAGR of % during projected year 2020 to 2026.
2. Who are the top performing companies in Cluster Headache Drug Market?
Top performing companies in the Global Cluster Headache Drug market are F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Pfizer Inc (United States), AstraZeneca (United Kingdom), Eli Lilly and Company (United States), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd (Israel), TrioxBio Inc (Israel), Aurobindo Pharma (India), Endo Pharmaceuticals Inc (Ireland) and Chengdu Tiantaishan pharmaceutical Co.,Ltd (China), to name a few.
3. What trending factors would impact Cluster Headache Drug Market growth most?
"Increase in the rate of R&D initiatives" is seen as one of major influencing trends for Cluster Headache Drug Market during projected period 2020-2026.